Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by the Food and Drug Administration as effective; and

require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.